Shots:

• The P-III studies SKYLIGHT 1 & 2 involves assessing fezolinetant (30 & 45mg- qd) vs PBO in women with mod. to sev. vasomotor symptoms (VMS) for the first 12wks. followed by 40wks. active treatment extension periods
• Both the trials met all four co-1EPs demonstrating a significant reduction from baseline in the frequency and severity of moderate to severe VMS to week 4 and week 12
• Fezolinetant is an NK3R antagonist targeting NKB binding on the KNDy neuron to moderate neuronal activity in the brain to treat VMS associated with menopause

 ­ Ref: Astellas | Image:Astellas